Regenxbio Inc. (NASDAQ:RGNX) was down 1.7% on Monday . The stock traded as low as $7.91 and last traded at $8.00, with a volume of 65,895 shares. The stock had previously closed at $8.14.

Several equities research analysts recently weighed in on RGNX shares. Chardan Capital reaffirmed a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Regenxbio in a report on Tuesday, July 5th. Zacks Investment Research downgraded shares of Regenxbio from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd. Finally, Morgan Stanley upped their price objective on shares of Regenxbio from $34.00 to $36.00 in a report on Friday, April 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $28.35.

The company’s market capitalization is $208.86 million. The firm has a 50 day moving average of $10.50 and a 200-day moving average of $12.09.

Regenxbio (NASDAQ:RGNX) last issued its earnings results on Thursday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.01. On average, analysts forecast that Regenxbio Inc. will post ($2.37) EPS for the current fiscal year.

In related news, insider Fmr Llc sold 10,570 shares of the firm’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $9.94, for a total value of $105,065.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.